Case Studies

Featured

CinCor Pharma, Inc. (CINC): Successful IPO

BACKGROUND CinCor is a clinical-stage biopharmaceutical company focused on developing baxdrostat, a hypertension (HTN) drug for patients with resistant hypertension (rHTN) or uncontrolled hypertension (uHTN) with the goal of providing improved treatment for patients suffering from hypertension and not yet at goal. At the request of the...

Read More
Bellus Health (NASDAQ: BLU) Investor Relations Program

BACKGROUND Bellus Health is a clinical-stage biopharmaceutical company focused on developing a P2X3 antagonist to address refractory chronic cough and other hypersensitization disorders. The Company’s...

Read More
CinCor Pharma, Inc. (CINC): Successful IPO

BACKGROUND CinCor is a clinical-stage biopharmaceutical company focused on developing baxdrostat, a hypertension (HTN) drug for patients with resistant hypertension (rHTN) or uncontrolled hypertension (uHTN)...

Read More
Vera (VERA): Investor Relations Program

LIFESCI’s ACTIVITIES Aggressive outreach to new investors and sell-side analysts Arranged 80 TTW and IPO roadshow meetings Arranged 13 meetings during the 2022 LifeSci Corporate...

Read More
PharmaMar (PHM.BME): Investor Relations Program

Background PharmaMar is a commercial-stage oncology company headquartered in Spain and listed on the Bolsas y Mercados Españoles exchange. Despite the successful commercial launch of...

Read More
Valneva NASDAQ IPO (Dual-Listing) Case Study

In preparation for a near-term NASDAQ IPO, Valneva sought to capitalize on the numerous catalysts expected over the course of 2021 from its pipeline of...

Read More
Inspire Medical – KOL Event and Platform Drive Visibility Prior to IPO

Inspire Medical became a LifeSci Advisors client pre-IPO. The teams collaborated to develop and execute a robust, best-in-class investor relations program to engage the investment...

Read More

Questions for our team?